Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymetrix Inc.
Affymetrix Technology Helps Advance Schizophrenia Research
August 29th, 2008
Affymetrix Inc. (Nasdaq:AFFX) announced that researchers around the world have used the Affymetrix Genome-Wide Human SNP Arrays 5.0 and 6.0 to uncover important links between copy number variations (CNVs) and schizophrenia. Researchers from the United States, Europe and Asia published their findings in recent issues of Nature and Nature Genetics. Schizophrenia is a chronic and disabling disorder that affects 2.4 million Americans alone. Even with the best treatments currently available, most patients do not recover fully.(1) About 40 percent of the disease is thought to be inherited, and the other 60 percent sporadically shows up in people whose family history does not...
Source: Health Business Week (2008-08-29)
|
